Tag:
innovation
Latest Headlines
Latest Headlines
Smith & Nephew CEO: Lack of innovation begats plunging industry margins
The medical device industry is boring. It doesn't innovate. And that, rather than government austerity, is why companies continue to face falling margins. Before you write that off as a conclusion coming from an outside consultant, consider that it comes from one of the industry's major figures: Smith & Nephew ($SNN) CEO Olivier Bohuon.
Experts jab over drug patent reform and the best approach to innovation
One of the most persistent arguments in the biopharma business these days is focused squarely on the length of patent protection a new treatment has when it goes on the market. The industry has
Lilly chief calls on U.S. to slash taxes
Read John Lechleiter's ( photo ) lips: Lower Taxes. In a speech at an industry conference, the Lilly CEO called for the U.S. government to slash the corporate tax rate if it wants to see more
Obama fingers FDA as agency in need of overhaul
Will the FDA get an Obama-backed makeover? Before a panel meeting on jobs and competitiveness, the president said the FDA isn't up to speed on current technology, so it's not able and ready to handle
Biopharma: Innovating to extinction?
A new study in the Journal of the American Medical Association examines an increasingly problematic phenomenon in pharma: "innovation to extinction." In short, the better pharma companies do their
Study: Lower prices don't harm innovation
In the age-old fight for superiority between Europe and the U.S., the old countries have chalked up another point. This time it's pharma R&D productivity and innovation that's the prize, and new
BMS swallows Canada's Erbitux price
Call it a new pricing strategy. Bristol-Myers Squibb is preparing to launch the cancer treatment Erbitux in Canada after a two-year wrangle over cost. Approved by Health Canada in September 2005,
SPOTLIGHT: Investors: Biologics are 'hot' right now
Kate Bingham, managing partner at SV Life Sciences, says that biologics are "hot" right now for investors.
Novartis backs out of India R&D deal
Too bad, India. Novartis CEO Daniel Vasella says he's scrapping plans to invest millions in R&D there. The reason? Intellectual property protections aren't adequate in India, Vasella says. Of
